Thermo Fisher Science在2025年提升了对收入的预期,提升了对2025年的指导,增加了其存量。 Thermo Fisher Scientific beat earnings expectations and raised 2025 guidance, boosting its stock.

Thermo Fisher Science报告第二季度收入丰厚,收入为5.36 EPS和108.6亿美元,令人望而却步,将2025年全年收入指导提高到22.22-22.84美元/股。 Thermo Fisher Scientific reported strong second-quarter earnings, with $5.36 EPS and $10.86 billion in revenue, beating expectations, and raised its full-year 2025 earnings guidance to $22.22–$22.84 per share. 股票交易额484.70美元,市场上限为183.03亿美元,股息收益为0.4%。 The stock, trading at $484.70, has a market cap of $183.03 billion and a 0.4% dividend yield. 机构投资者集体拥有89.23%的股份,一些公司调整了立场—— 切尔西咨询公司减少了股份,而90个英国一家有限公司和UBS资产管理公司增加了股份。 Institutional investors collectively own 89.23% of shares, with several firms adjusting positions—Chelsea Counsel Co. reduced its stake, while Ninety One UK Ltd and UBS Asset Management increased holdings. 内幕人士在三个月内出售了1400万美元的库存,分析师维持了“机动购买”共识,平均目标价格为583.53美元。 Insiders sold $14 million in stock over three months, and analysts maintain a "Moderate Buy" consensus with a $583.53 average target price.